PMID- 18306350
OWN - NLM
STAT- MEDLINE
DCOM- 20080724
LR  - 20080618
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 114
IP  - 3
DP  - 2008 Jun 25
TI  - 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions 
      additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
PG  - 204-15
LID - 10.1002/cncr.23413 [doi]
AB  - BACKGROUND: The diagnosis of malignant mesothelioma (MM) in serous effusions is 
      difficult but may be achieved by the application of adjuvant methods. METHODS: 
      The authors cytologically diagnosed 33 effusions as suspicious or positive for MM 
      cells by using DNA-image cytometry (DNA-ICM), immunocytochemistry and AgNOR 
      analysis. The authors further detected 9p21 deletions by chromosomal fluorescence 
      in situ hybridization (FISH). In addition, 31 cases of metastatic carcinomas and 
      39 of tumor cell-negative effusions were investigated. All diagnoses were 
      confirmed by histologic and/or clinical follow-up. RESULTS: DNA aneuploidy was 
      found in 71% of MMs, 100% of metastatic carcinomas, and in none of the negative 
      effusions. Calretinin was positive in 100% of MMs, in none of the metastatic 
      carcinomas, and in 94.9% of negative effusions. BerEP4 showed positivity in 15.6% 
      of MMs, 87.1% of metastatic carcinomas, and in none of the negative effusions. 
      With AgNOR analysis, 89.3% of MMs and 96.7% of metastatic carcinomas showed 
      >or=2.5 AgNOR dots as satellites and >or=4.5 as total AgNOR counts. 9p21 
      deletions were demonstrated in 90.9% of MM cases, 45.2% of metastatic carcinomas, 
      and in none of the negative effusions. By cytology alone, 81.8% of MMs were 
      identified unequivocally. Addition of DNA-ICM improved the prevalence of tumor 
      cell detection to 87.9% and of AgNOR analysis to 97%. The introduction of 9p21 
      deletions by FISH improved this prevalence to 100%. CONCLUSIONS: Because of these 
      results, the authors propose the sequential application of immunocytochemistry, 
      DNA-ICM, and AgNOR analysis to establish a cytological diagnosis of malignant 
      mesothelioma in serous effusions. In persistent doubtful diagnoses, the authors 
      recommend fluorescence in situ hybridization to analyze the 9p21 deletion.
CI  - (c) 2008 American Cancer Society.
FAU - Onofre, Fabiana Botelho de Miranda
AU  - Onofre FB
AD  - Institute of Cytopathology, Heinrich-Heine University, Dusseldorf, Germany.
FAU - Onofre, Alexandre Sherlley Casimiro
AU  - Onofre AS
FAU - Pomjanski, Natalia
AU  - Pomjanski N
FAU - Buckstegge, Birgit
AU  - Buckstegge B
FAU - Grote, Hans Juergen
AU  - Grote HJ
FAU - Bocking, Alfred
AU  - Bocking A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antigens, Nuclear)
RN  - 0 (nucleolar organizer region associated proteins)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aneuploidy
MH  - Antigens, Nuclear/*analysis
MH  - *Ascitic Fluid/pathology
MH  - *Chromosome Deletion
MH  - Chromosomes, Human, Pair 9/*genetics
MH  - DNA/*analysis
MH  - Female
MH  - Humans
MH  - *Image Cytometry
MH  - Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Male
MH  - Mesothelioma/*diagnosis/pathology
MH  - Middle Aged
MH  - Peritoneal Neoplasms/*diagnosis/genetics/pathology
MH  - Pleural Effusion, Malignant/*complications/genetics/pathology
MH  - Pleural Neoplasms/*diagnosis/genetics/pathology
EDAT- 2008/02/29 09:00
MHDA- 2008/07/25 09:00
CRDT- 2008/02/29 09:00
PHST- 2008/02/29 09:00 [pubmed]
PHST- 2008/07/25 09:00 [medline]
PHST- 2008/02/29 09:00 [entrez]
AID - 10.1002/cncr.23413 [doi]
PST - ppublish
SO  - Cancer. 2008 Jun 25;114(3):204-15. doi: 10.1002/cncr.23413.